These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22367886)

  • 1. Treatment-refractory idiopathic hypereosinophilic syndrome: pitfalls and progress with use of novel drugs.
    Bleeker JS; Syed FF; Cooper LT; Weiler CR; Tefferi A; Pardanani A
    Am J Hematol; 2012 Jul; 87(7):703-6. PubMed ID: 22367886
    [No Abstract]   [Full Text] [Related]  

  • 2. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report.
    Pitini V; Teti D; Arrigo C; Righi M
    Br J Haematol; 2004 Dec; 127(5):477. PubMed ID: 15566349
    [No Abstract]   [Full Text] [Related]  

  • 3. Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab.
    Buttgereit T; Bonnekoh H; Church MK; Bergmann KC; Siebenhaar F; Metz M
    J Dtsch Dermatol Ges; 2019 Nov; 17(11):1171-1172. PubMed ID: 31479567
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug-induced hypereosinophilia related to tocilizumab therapy for rheumatoid arthritis.
    Morrisroe K; Wong M
    Rheumatology (Oxford); 2015 Nov; 54(11):2113-4. PubMed ID: 26224305
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypereosinophilic syndrome presenting as an unusual triad of eosinophilia, severe thrombocytopenia, and diffuse arterial thromboses, with good response to mepolizumab.
    Leon-Ferre RA; Weiler CR; Halfdanarson TR
    Clin Adv Hematol Oncol; 2013 May; 11(5):317-9. PubMed ID: 23880717
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia.
    Simon D; Salemi S; Yousefi S; Simon HU
    J Allergy Clin Immunol; 2008 Apr; 121(4):1054-6. PubMed ID: 18234315
    [No Abstract]   [Full Text] [Related]  

  • 7. The Effect of Mepolizumab on the Lungs in a Boy with Hypereosinophilic Syndrome.
    Armoni Domany K; Shiran SI; Adir D; Lavie M; Levin D; Diamant N; Gut G; Benor S
    Am J Respir Crit Care Med; 2020 Jul; 202(2):e34-e35. PubMed ID: 32150442
    [No Abstract]   [Full Text] [Related]  

  • 8. Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission.
    Malagola M; Martinelli G; Rondoni M; Ottaviani E; Piccaluga PP; Ricci P; Visani G; Baccarani M
    Haematologica; 2004 Aug; 89(8):ECR25. PubMed ID: 15339694
    [No Abstract]   [Full Text] [Related]  

  • 9. Eosinophilia with aberrant T cells and elevated serum levels of interleukin-2 and interleukin-15.
    Means-Markwell M; Burgess T; deKeratry D; O'Neil K; Mascola J; Fleisher T; Lucey D
    N Engl J Med; 2000 May; 342(21):1568-71. PubMed ID: 10824075
    [No Abstract]   [Full Text] [Related]  

  • 10. Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis.
    Patel B; Butterfield JH; Weiler CR; Kane SV
    Monoclon Antib Immunodiagn Immunother; 2016 Dec; 35(6):300-303. PubMed ID: 27911676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An unusual presentation of idiopathic hypereosinophilic syndrome.
    Thakral C
    Clin Adv Hematol Oncol; 2013 May; 11(5):320-1. PubMed ID: 23880718
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypereosinophilia in patients with multiple sclerosis treated with natalizumab.
    Abbas M; Lalive PH; Chofflon M; Simon HU; Chizzolini C; Ribi C
    Neurology; 2011 Oct; 77(16):1561-4. PubMed ID: 21975205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab in the reversal of encephalopathy associated with hypereosinophilic syndrome.
    Perini GF; Santos FP; Hamerschlak N
    Br J Haematol; 2009 Dec; 147(5):592. PubMed ID: 19545288
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody.
    Strati P; Cortes J; Faderl S; Kantarjian H; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):287-91. PubMed ID: 23123105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benralizumab in Severe and Refractory PDGFRA-Negative Hypereosinophilic Syndrome.
    Alen Coutinho I; Regateiro FS; Loureiro C; Todo-Bom A
    J Clin Immunol; 2021 Apr; 41(3):688-690. PubMed ID: 33394318
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
    Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
    J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Treatment for Hypereosinophilic Syndrome.
    Aschenbrenner DS
    Am J Nurs; 2021 Mar; 121(3):23. PubMed ID: 33625006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clonal hypereosinophilic syndrome with specific and effective therapy: a report of two cases.
    Ellis MH; Ashur-Fabian O; Trakhtenbrot L; Amariglio N
    Isr Med Assoc J; 2006 Dec; 8(12):836-7. PubMed ID: 17214097
    [No Abstract]   [Full Text] [Related]  

  • 19. Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood.
    Schwarz C; Müller T; Lau S; Parasher K; Staab D; Wahn U
    Pediatr Allergy Immunol; 2018 Feb; 29(1):28-33. PubMed ID: 28986919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glivek in the therapy of some forms of Ph- and bcr/abl-negative myeloproliferative diseases and a myeloproliferative variant of idiopathic hypereosinophilic syndrome].
    Nemchenko IS; Khoroshko ND; Turkina AG; Vinogradova OIu; Sokolova MA; Abakumov EM; Semenova EA; Zakharova AV; Domracheva EV
    Ter Arkh; 2004; 76(7):87-90. PubMed ID: 15379136
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.